1,128 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Erfonrilimab Non-Small Cell Lung Carcinoma	Shanghai Pulmonary Hospital, Shanghai, China	P2/3	B (60)
Garsorasib Non-Small Cell Lung Carcinoma	Shandong Suncadia Medicine Co., Ltd.	P3	B (60)
gt103 Non-Small Cell Lung Carcinoma	Roswell Park Cancer Institute	P2	B (60)
Hrs-7058 Non-Small Cell Lung Carcinoma	Shandong Suncadia Medicine Co., Ltd.	P3	B (60)
ibi310 Non-Small Cell Lung Carcinoma	Shanghai Pulmonary Hospital, Shanghai, China	P2	B (60)
Ifebemtinib Non-Small Cell Lung Carcinoma	InxMed (Shanghai) Co., Ltd.	P3	B (60)
Immunoglobulin G1 (256-Tyrosine,258-Threonine,260-Glutamic Acid), Anti-(Neural Apoptosis-Regulated Proteinase 1) (Human-Mus Musculus Monoclonal Hrp00130 .Gamma.1-Chain), Disulfide With (3-Valine,5-Serine,49-Serine,66-Aspartic Acid) Human-Mus Musculus Monoclonal Hrp00130 .Kappa.-Chain, Dimer Non-Small Cell Lung Carcinoma	Hunan Cancer Hospital	P4	B (60)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Tigit (T-Cell Immunoreceptor With Ig Domain And Itim, V-Set Ig Member 9, Vsig9, V-Set And Transmembrane Member 3, Vstm3)], Humanized Monoclonal Antibody; Gamma1 Heavy Chain Humanized (1-448) [Vh (Homo Sapiens Ighv3-4801 (90.8%) -(Ighd) -Ighj401 (92.3%)) Cdr-Imgt [8.8.12] (26-33.51-58.97-108) (1-119) -Homo Sapiens Ighg101, G1M17,1, G1V14 Ch2 A1.3, A1.2 (Ch1 K120 (216) (120-217), Hinge 1-15 (218-232), Ch2 L1.3>A (236), L1.2>A (237) (233-342), Ch3 D12 (358), L14 (360) (343-447), Chs K>Del (448)) (120-448)], (222-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-1601 (89.5%) -Igkj401 (100%)) Cdr-Imgt [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo Sapiens Igkc01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In A Chinese Hamster Ovary (Cho)-K1 Cell Line, Glycoform Alfa Non-Small Cell Lung Carcinoma	Gilead Sciences	P2	B (60)
Immunoglobulin G4 (227-Proline), Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Psb103 .Gamma.4-Chain), Disulfide With Human Monoclonal Psb103 .Kappa.-Chain, Dimer Non-Small Cell Lung Carcinoma	Tang-Du Hospital	P3	B (60)
Jinfukang Non-Small Cell Lung Carcinoma	China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.	P4	B (60)
Lactobacillus Reuteri Group Non-Small Cell Lung Carcinoma	Instituto Nacional de Cancerologia de Mexico	P3	B (60)
Lidocaine Non-Small Cell Lung Carcinoma	First Affiliated Hospital of Ningbo University	P4	B (60)
mb12 Non-Small Cell Lung Carcinoma	mAbxience Research S.L.	P3	B (60)
Memantine Non-Small Cell Lung Carcinoma	NRG Oncology	P3	B (60)
Olomorasib Non-Small Cell Lung Carcinoma	UNC Lineberger Comprehensive Cancer Center	P3	B (60)
Palbociclib Non-Small Cell Lung Carcinoma	Pfizer	P2	B (60)
Pembrolizumab Biosimilar Non-Small Cell Lung Carcinoma	Laboratorio Elea Phoenix S.A.	P3	B (60)
Personalized Neoantigen Peptide Vaccine Non-Small Cell Lung Carcinoma	The First Affiliated Hospital of Nanchang University	P2	B (60)
Plinabulin Non-Small Cell Lung Carcinoma	BeyondSpring Pharmaceuticals Inc.	P3	B (60)
Propofol Non-Small Cell Lung Carcinoma	Samsung Medical Center	P4	B (60)
Pucotenlimab Non-Small Cell Lung Carcinoma	Anhui Provincial Cancer Hospital	P2/3	B (60)
Shr-A2102 Non-Small Cell Lung Carcinoma	Shanghai Hengrui Pharmaceutical Co., Ltd.	P2	B (60)
Tgrx-326 Non-Small Cell Lung Carcinoma	Shenzhen TargetRx Co., Ltd.	P3	B (60)
ty-9591 Non-Small Cell Lung Carcinoma	TYK Medicines, Inc	P3	B (60)
Vorolanib Non-Small Cell Lung Carcinoma	Li-kun Chen	P2	B (60)
Zimberelimab Non-Small Cell Lung Carcinoma	Fundación GECP	P3	B (60)
Boserolimab Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P2	B (59)
Capmatinib Non-Small Cell Lung Carcinoma	Sun Yat-sen University	P4	B (59)
Cifurtilimab Non-Small Cell Lung Carcinoma	Seagen Inc.	P2	B (59)
Cik Cells Non-Small Cell Lung Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2/3	B (59)
Dabrafenib Non-Small Cell Lung Carcinoma	Cancer Research UK	P4	B (59)
Diphenhydramine Non-Small Cell Lung Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P3	B (59)
Fluorouracilum Non-Small Cell Lung Carcinoma	Fudan University	P3	B (59)
her3-dxd Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P2	B (59)
Para-Toluenesulfonamide Non-Small Cell Lung Carcinoma	Gang Hou	P3	B (59)
Petosemtamab Non-Small Cell Lung Carcinoma	Merus B.V.	P2	B (59)
qlc1101 Non-Small Cell Lung Carcinoma	Qilu Pharmaceutical Co., Ltd.	P3	B (59)
Vorinostat Non-Small Cell Lung Carcinoma	H. Lee Moffitt Cancer Center and Research Institute	P2/3	B (59)
Adagrasib Non-Small Cell Lung Carcinoma	M.D. Anderson Cancer Center	P3	B (58)
Avelumab Non-Small Cell Lung Carcinoma	Fate Therapeutics	P3	B (58)
bnt116 Non-Small Cell Lung Carcinoma	Regeneron Pharmaceuticals	P2	B (58)
Capecitabine Non-Small Cell Lung Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P3	B (58)
Carfilzomib Non-Small Cell Lung Carcinoma	City of Hope Medical Center	P1/2	B (58)
Envafolimab Non-Small Cell Lung Carcinoma	City of Hope Medical Center	P3	B (58)
Everolimus Non-Small Cell Lung Carcinoma	Jiangsu Simcere Pharmaceutical Co., Ltd.	P2	B (58)
Gm-Csf Non-Small Cell Lung Carcinoma	Second Affiliated Hospital of Soochow University	P2	B (58)
hs-10365 Non-Small Cell Lung Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P2	B (58)
ibi351 Non-Small Cell Lung Carcinoma	Guangdong Association of Clinical Trials	P2	B (58)
Iodized Ethyl Esters Of Poppyseed Fatty Acids Non-Small Cell Lung Carcinoma	City of Hope Medical Center	P2	B (58)
Jab 3312 Non-Small Cell Lung Carcinoma	Allist Pharmaceuticals, Inc.	P3	B (58)

Showing 151 to 200 of 1,128 assets

PreviousPage 4 of 23Next